178 related articles for article (PubMed ID: 36789106)
21. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
22. The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone.
Okui T; Hiasa M; Ryumon S; Ono K; Kunisada Y; Ibaragi S; Sasaki A; Roodman GD; White FA; Yoneda T
J Bone Oncol; 2021 Feb; 26():100330. PubMed ID: 33204606
[TBL] [Abstract][Full Text] [Related]
23. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
24. Involvement of RAGE in radiation-induced acquisition of malignant phenotypes in human glioblastoma cells.
Seki H; Kitabatake K; Tanuma SI; Tsukimoto M
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(9):130650. PubMed ID: 38830560
[TBL] [Abstract][Full Text] [Related]
25. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
26. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.
Bassi R; Giussani P; Anelli V; Colleoni T; Pedrazzi M; Patrone M; Viani P; Sparatore B; Melloni E; Riboni L
J Neurooncol; 2008 Mar; 87(1):23-33. PubMed ID: 17975708
[TBL] [Abstract][Full Text] [Related]
27. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
[TBL] [Abstract][Full Text] [Related]
28. Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging.
Scavello F; Zeni F; Tedesco CC; Mensà E; Veglia F; Procopio AD; Bonfigli AR; Olivieri F; Raucci A
Aging (Albany NY); 2019 Mar; 11(6):1648-1663. PubMed ID: 30903794
[TBL] [Abstract][Full Text] [Related]
29. Targeting IGF2-IGF1R Signaling to Reprogram the Tumor Microenvironment for Enhanced Viro-Immunotherapy.
Noh MH; Kang JM; Miller AA; Nguyen G; Huang M; Shim JS; Bueso-Perez AJ; Murphy SA; Rivera-Caraballo KA; Otani Y; Kim E; Yoo SH; Yan Y; Banasavadi-Siddegowda Y; Nakashima H; Chiocca EA; Kaur B; Zhao Z; Lee TJ; Yoo JY
Neuro Oncol; 2024 Jun; ():. PubMed ID: 38853689
[TBL] [Abstract][Full Text] [Related]
30. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
32. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation.
Ullah MA; Loh Z; Gan WJ; Zhang V; Yang H; Li JH; Yamamoto Y; Schmidt AM; Armour CL; Hughes JM; Phipps S; Sukkar MB
J Allergy Clin Immunol; 2014 Aug; 134(2):440-50. PubMed ID: 24506934
[TBL] [Abstract][Full Text] [Related]
33. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
[TBL] [Abstract][Full Text] [Related]
35. Role Played by Receptors for Advanced Glycosylation End Products in Corneal Endothelial Cells after HSV-1 Infection.
Miyazaki D; Kandori-Inoue M; Shimizu Y; Ohtani F; Chono I; Inoue Y; Yamagami S
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072468
[TBL] [Abstract][Full Text] [Related]
36. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
[TBL] [Abstract][Full Text] [Related]
37. The HMGB1 receptor RAGE mediates ischemic brain damage.
Muhammad S; Barakat W; Stoyanov S; Murikinati S; Yang H; Tracey KJ; Bendszus M; Rossetti G; Nawroth PP; Bierhaus A; Schwaninger M
J Neurosci; 2008 Nov; 28(46):12023-12031. PubMed ID: 19005067
[TBL] [Abstract][Full Text] [Related]
38. Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma.
Zhou Z; Tian J; Zhang W; Xiang W; Ming Y; Chen L; Zhou J
Oncol Lett; 2021 Jul; 22(1):510. PubMed ID: 33986870
[TBL] [Abstract][Full Text] [Related]
39. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
[TBL] [Abstract][Full Text] [Related]
40. The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics.
Rivera-Caraballo KA; Nair M; Lee TJ; Kaur B; Yoo JY
Mol Ther Oncolytics; 2022 Sep; 26():63-75. PubMed ID: 35795093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
